Myocardial infarction (MI) remains the most common cause of death worldwide. Many MI survivors will suffer from recurrent heart failure (HF), which has been recognized as a determinant of adverse prognosis. Despite the success of improved early survival after MI by primary percutaneous coronary intervention, HF after MI is becoming the major driver of late morbidity, mortality, and healthcare costs. The development of regenerative medicine has brought hope to MI treatment in the past decade. Mesenchymal stem cell (MSC)-derived exosomes have been established as an essential part of stem cell paracrine factors for heart regeneration. However, its regenerative power is hampered by low delivery efficiency to the heart. We designed, fabricated, and tested a minimally invasive exosome spray (EXOS) based on MSC exosomes and biomaterials. In a mouse model of acute myocardial infarction, EXOS improved cardiac function and reduced fibrosis, and promoted endogenous angiomyogenesis in the post-injury heart. We further tested the feasibility and safety of EXOS in a pig model. Our results indicate that EXOS is a promising strategy to deliver therapeutic exosomes for heart repair.
Keyphrases
- heart failure
- stem cells
- mesenchymal stem cells
- minimally invasive
- acute myocardial infarction
- percutaneous coronary intervention
- atrial fibrillation
- healthcare
- mouse model
- left ventricular
- acute heart failure
- umbilical cord
- cell therapy
- coronary artery disease
- st segment elevation myocardial infarction
- bone marrow
- cardiovascular events
- emergency department
- cardiac resynchronization therapy
- type diabetes
- coronary artery bypass grafting
- young adults
- tissue engineering
- social media
- wound healing